Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.
We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages.
Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II.

We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics.

We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. 

Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). 

Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

Fusion Antibodies

Have you read our top tips for transient protein expression?  https://lnkd.in/eGUwvC34

Today our team are at World BI Drug Discovery Innovation in Munich. We also have representatives at ELRIG UK Day 2 Drug Discovery. It's a busy week! #drugdiscovery #antibodydiscovery #antibodytherapeutics

ELRIG UK Drug Discovery Day 1! A great day catching up with familiar faces and meeting new people. If you are here and want to discuss your antibody development challenges, stop by stand E18 and say hello! #drugdiscovery #antibodydevelopment #antibodytherapeutics

Event season is here again! If you want to discuss how you can optimize your molecule to be the best it can possibly be, come and talk to us. We love to help our clients overcome problems and set them on the path to the clinic.  Here's a look at where you can find us. Visit our website for more info: https://lnkd.in/eis4jUpw  #drugdiscovery   #antibodydiscovery #antibodytherapeutics #biotech ELRIG UK World BI Cambridge Healthtech Institute

On the surface, an antibody molecule can look like an ideal candidate but what if you looked a little closer? In this example, the presence of multimers and aggregates, only identified by thorough analysis, skew the affinity results and mask a low quality preparation of antibody. Deep analysis of function, purity and protein quality is therefore vital. Before moving to transient protein expression, we always recommend running a pilot program. Here we share with you our top tips for getting it right. https://lnkd.in/eGUwvC34
#antibodyexpression #antibodytherapeutics

Happy Friday! We are hiring for a Business Development Officer. All details can be found on the website. We also have roles open in #marketing and #operations. Check out our careers page for more info: https://lnkd.in/eSdf8Cm6 
#businessdevelopment #newjobopportunity #biotechjobs
#nijobs #hiring #careers

We're off to San Francisco next week for the hubXchange Antibody Therapeutics event. Our CSO, Richard Buick, will host a round table on the topic of the optimum human CDR-H3 repertoire for antibody discovery. Also in attendance will be Aleksandra Bolbukova and Chris Winch from our commercial team. Comment below or email info@fusionantibodies.com if you'd like a meet up or to share your thoughts with us on the round table topic. #CDR-h3 #therapeutics #antibody #discovery 
https://lnkd.in/eeF2EAW5

Sending condolences to the Royal Family upon the passing of Her Majesty Queen Elizabeth II. May she rest in peace. https://lnkd.in/e_7AJE4b

We are hiring! We are looking for #CLD team leader, a Commercial Ops Co-ordinator and a Marketing Communications Executive. Come and join our growing team. Closing date is 9th September 2022 so don't hang about! https://lnkd.in/eSdf8Cm6 #nijobs #careers #biotechcareers

In-depth characterization is a vital stage in scaling up your molecule. Spending time on a transient protein expression pilot program now can help you rule out dead-end molecules and avoid nasty surprises at a later stage. Have a look at our website for more info: https://bit.ly/3Aaerst

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

FAB

COM:FUSIONANTIBODIES

Fusion Antibodies

Last Close

3.40

26/07 15:30

Market Cap

28.61K

Beta: -

Volume Today

78.65K

Avg: -

Filings Not Available